



Company Profile

RedHill Biopharma, established in 2009, is a publicly traded (NASDAQ / TASE: RDHL) specialty biopharmaceutical company, headquartered in Israel, primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer.

RedHill's pipeline currently includes drugs in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.


RedHill's products are based on several technology platforms and address several disease targets, thus providing for risk diversification.

RedHill's experienced management team, board of directors and advisory board, based in Israel, the US, Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.

Stock Performance

NASDAQ: RDHL.US ¹

Last Trade:	9.71
Trade Time:	12:40 PM ET Jul 24, 2017
Change:	0.34 ↑ (3.629%)
Volume	96,886



TASE: RDHL ¹

Last Trade:	331.30
Trade Time:	4:24 PM IT Jul 24, 2017
Change:	6.60 ↑ (2.033%)
Volume	346,953



Press Releases [\[View all \]](#)

Jul 18, 2017

[RedHill Biopharma to Host Second Quarter 2017 Financial Results Conference Call on July 25, 2017](#)

Jul 17, 2017

[RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D](#)

Jul 12, 2017

[RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease](#)

Events [\[View all \]](#)

Jul 25, 2017

[Second Quarter 2017 Financial Results Conference Call](#)

Sep 10–12, 2017

[Rodman & Renshaw 19th Annual Global Investment Conference](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Feb 23, 2017

[Annual Report for Foreign Private Issuers \(20-F\)](#)

RedHill Biopharma Ltd

Investor Relations Department
21 Haarbaa St
Tel Aviv 64739
Israel

[Visit IR website](#)

[Sign-up for email alerts](#)

